Prospective Evaluation of MRI Lumbosacral Nerve Root Enhancement in Acute Guillain-Barre Syndrome
Neurol 47:813-817, Gorson,K.C.,et al, 1996
Idiopathic Acute Transverse Myelitis:MR Imaging Findings
Radiology 201:661-669, Tartaglino,L.M.,et al, 1996
Redefining the Guillain-Barre Spectrum in Children: Neuroimaging Findings of Cranial Nerve Involvement
AJNR 32:639-42, Zuccoli, G.,et al, 2011
Enhancement of the Eight Cranial Nerve and Labyrinth on MR Imaging in Sudden Sensorineural Hearing Loss Associated with Human Herpesvirus 1 Infection: Case Report
AJNR 22:1380-1382, Lavi,E.S. &Sklar,E.M.L., 2001
Ramsay Hunt Syndrome Associated with Brain Stem Enhancement
AJNR 20:278-280, Sartoretti-Schefer,S.,et al, 1999
Guillain-Barre Syndrome:MR Imaging Findings of the Spine in Eight Patients
Radiology 208:137-141, Byun,W.M.,et al, 1998
Cranial Nerve Enhancement on Three-Dimentional MRI in Miller Fisher Syndrome
Neurol 47:1601-1602, Nagaoka,U.,et al, 1996
Cranial Nerve Enhancement in the Guillain-Barre Syndrome
AJNR 16:923-925, Fulbright,R.K.,et al, 1995
Magnetic Resonance Imaging of the Cauda Equina in Guillain-Barre Syndrome
Neurol 44:1334-1336, Crino,P.B.,et al, 1994
Nerve Root Enhancement with MRI in Inflammatory Demyelinating Polyradiculoneuropathy
Neurol 32:618-619, Morgan,G.W.,et al, 1993
MRI of Guillain-Barre Syndrome
J Comput Assist Tomogr 17:651-652, Patel,H.,et al, 1993
Spot Sign in Acute Intracerebral Hemorrhage in Dynamic T1-Weighted Magnetic Resonance Imaging
Stroke 47:417-423, Schindlbeck, K.A.,et al, 2016
Thrombus Length Estimation on Delayed Gadolinium-Enhanced T1
Stroke 47:756-761,643, Yan, S.,et al, 2016
Sturge-Weber Syndrome
UptoDate , Nov, Bodensteiner, J.B., 2014
Sturge-Weber Syndrome
MedLink Neurology, July, Comi, A.M., 2013
Expanding the Clinical, Radiological and Neuropathological Phenotype of Chronic Lymphocytic Inflammation with Pontine Perivascular Enhancement Responsive to Steroids (CLIPPERS)
JNNP 83:15-22, Simon, N.G.,et al, 2012
Clinicopathologic Conference, Glioblastonoma, WHO grade IV of IV, with Methylation of the MGMT Promoter
NEJM 366:2112-2120, Case 17-2012, 2012
Current Concept of Neuromyelitis Optica (NMO) and NMO Spectrum Disorders
JNNP doi:10.1136/JNNP-2012-302310, Jacob, A.,et al, 2012
Diagnosis and Management of Cerebral Venous Thrombosis: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association
Stroke 42:1158-1192, Saposnik,G.,et al, 2011
Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis
Neurol 76:1858-1865, OConnor, P.W.,et al, 2011
Primary Intramedullary Spinal Cord Lymphoma
Neurol 77:784-791, Flanagan, E.P.,et al, 2011
Neurosacrcoidosis: Presentations and Management
Neurologist 16:2-15, Terushkin,V.,et al, 2010
Ring and Nodular Multiple Sclerosis Lesions: A Retrospective Natural History Study
Neurol 74:851-858, Davis,M.,et al, 2010
JC Virus Infection of the Brain
AJNR 31:1564-1576, Bag,A.K.,et al, 2010
Compressive Myelopathy Mimicking Transverse Myelitis
Neurologist 16:120-122, Kelley, B.,et al, 2010
Oral Fingolimod (FTY720) in Multiple Sclerosis: Two-Year Results of a Phase II Extension Study
Neurol 72:73-79, OConnor,P.,et al, 2009
Early MRI in Optic Neuritis: The Risk for Disability
Neurol 72:542-550, Swanton,.K.,et al, 2009
Progressive Multifocal Leukoencephalopathy and Relapsing-Remitting Multiple Sclerosis: A Comparative Study
Arch Neurol 66:593-599, Boster,A.,et al, 2009
B-Cell Depletion with Rituximab in Relapsing-Remitting Multiple Sclerosis
NEJM 358:676-688, Hauser,S.L.,et al, 2008
Effect of Laquinimod on MRI-Monitored Disease Activity in Patients With Relapsing-Remitting Multiple Sclerosis: A Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase IIb Study
Lancet 371:2085-2092,2059, Comi,G.,etc., 2008
Efficacy and Safety of Oral Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis: A Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase LLB Study
Lancet 372:1463-1472, Kappos,L.,et al, 2008
Bal�s Disease Showing Benign Clinical Course and Co-Existence with Multiple Sclerosis-Like Lesions in Chinese
Multiple Sclerosis 14:418-424, Wang,C.,et al, 2008
Daclizumab Phase II Trial in Relapsing and Remitting Multiple Sclerosis
Neurol 69:785-789, Rose,J.W.,et al, 2007
Primary Central Nervous System Vasculitis: Analysis of 101 Patients
Ann Neurol 62:442-451,430, Salvarani,C.,et al, 2007
Progressive Multifocal Leukoencephalopathy Revisited: Has the Disease Outgrown Its Name?
Ann Neurol 60:162-173, Koralnik,I.J., 2006
Oral Fingolimod (FTY720) for Relapsing Multiple Sclerosis
NEJM 355:1124-1140, Kappos,L.,et al, 2006
Cliniclopath Conf., Granulomatous Amebic Encephalitis Due to Acanthamoeba
NEJM 355:2678-2689, Case 39-2006, 2006
Spinal Cord Schistosomiasis: MR Imaging Appearance with Surgical and Pathologic Correlation
AJNR 26:1646-1654, Saleem,S.,et al, 2005
Update on Susacs Syndrome
Curr Opin Neurol 18:311-314, Gross,M. &Eliashar,R., 2005
Oral Simvastin Treatment in Relapsing-Remitting Multiple Sclerosis
Lancet 363:1607-1608,1570, Vollmer,T.,et al, 2004
A Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis
NEJM 348:14-23, Miller,D.H.,et al, 2003
Multiple Sclerosis and Magnetic Resonance Imaging
Arch Neurol 58:35-36, Racke,M.K.,et al, 2001
Assessing the Risk of Early Multiple Sclerosis in Patients with Clinically Isolated Syndromes: the Role of a Follow Up MRI
JNNP 70:390-393, Brex,P.A.,et al, 2001
European/Canadian Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of the Effects of Glatiramer Acetate on Magnetic Resonance Imaging-Measured Disease Activity and Burden in Patients wi
Ann Neurol 49:290-297, Comi,G.,et al, 2001
Initial and Follow-up MR Imaging Findings in AIDS-Related Progressive Multifocal Leukoencephalopathy Treated with Highly Active Antiretroviral Therapy
AJNR 22:977-984, Thurnher,M.M.,et al, 2001
Brainstem Gliomas in Adults: Prognostic Factors and Classification
Brain 124:2528-2539, Guillamo,J.-S.,et al, 2001
Glatiramer Acetate (Copaxone) Treatment in Relapsing-Remitting MS
Neurol 54:813-817, Ge,Y.,et al, 2000
Interferon-alpha 2a Reduces MRI Disease Activity in Relapsing-Remitting Multiple Sclerosis
Neurol 52:1049-1056, Myhr,K.M.,et al, 1999
Evidence of Interferon B-1a Dose Response In Relapsing-Remitting MS, The OWIMS Study
Neurol 53:679-686, The Once Weekly Interferon for MS Study Group (OWI, 1999